Abstract
We performed an meta-analysis to fully investigate the diarrhea of EGFR-TKIs in cancer patients. The relevant studies of the randomized controlled trials (RCTs) in cancer patients treated with EGFR-TKIs were retrieved and the systematic evaluation was conducted. EMBASE, MEDLINE, and PubMed were searched for articles published till August 2017. The relevant RCTs in cancer patients treated with EGFR-TKIs were retrieved and the systematic evaluation was conducted. Twenty-four RCTs and 13,748 patients were included. The current analysis suggested that the use of EGFR-TKIs increased the risk of all-grade diarrhea (RR 3.45; 95%CI, 2.94-4.06; p＜0.00001) and high-grade (≥grade 3) diarrhea (RR 8.22；95%CI, 6.02-11.23; p＜0.00001). On subgroup analysis, the risk of all-grade and high-grade diarrhea varied significantly within drug type. The risk of all-grade diarrhea varied significantly according to cancer type, whereas the risk of high-grade diarrhea did not. The risk of all-grade and high-grade diarrhea did not varied significantly based on treatment line, treatment duration and median age. The available data suggested that the use of EGFR-TKIs is associated with a significantly increased risk of diarrhea in cancer patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
